Today's Rundown After BMS said no, Roche puts $1.4B on the table for Promedior, boosting fibrotic pipeline Sarepta pays StrideBio $48M for preclinical gene therapies Arrowhead R&D lead steps down, biotech vets step in EpicentRx raises $35M to fund late-phase lung cancer trial Could this immuno-oncology combo treat metastatic prostate cancer? EuroBiotech Report—AstraZeneca's lupus filing, Roche SMA data, Kiadis cuts, Genfit and Merck FiercePharmaAsia—Sandoz bets, Lupin sells in Japan; Dr. Reddy’s Zantac loss; Aslan’s varlitinib flop Chutes & Ladders—Abbott CEO White out after 21 years on the job Featured Story | | | Friday, November 15, 2019 Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process. |
|
|---|
|
Top Stories Friday, November 15, 2019 Sarepta is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal. Friday, November 15, 2019 Californian RNA biotech Arrowhead will lose its chief operating officer and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team. Friday, November 15, 2019 EpicentRx has raised $35 million for late-phase development of RRx-001. The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. Thursday, November 14, 2019 Researchers at MD Anderson Cancer Center discovered that when prostate tumors spread to bone and destroy it, massive amounts of a protein called TFG-beta are produced, which prevents immune-boosting drugs from attacking the cancer. Combining a checkpoint inhibitor with an anti-TGF-beta drug could be the answer, they believe. Thursday, November 14, 2019 In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot. Friday, November 15, 2019 Novartis' Sandoz doubled down on Japan with a €400 million Aspen deal, as Lupin retreated from the country. Dr. Reddy's detailed its loss from the U.S. recall of generic Zantac. Aslan's lead drug, pan-HER inhibitor varlitinib, failed yet another critical trial. And more. Friday, November 15, 2019 Abbott CEO Miles White is set to step down after 21 years; Lonza head Marc Funk is out after just a year; and Progenics' Mark Baker could be out after a board shuffle. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 